Biogen Inc. (NASDAQ:BIIB) was among Jim Cramer’s stock calls on Mad Money recently. Toward the end of the lightning round, a ...

Biogen (NASDAQ:BIIB) picked up a strong endorsement from Wall Street on Wednesday, as UBS analyst Michael Yee upgraded the ...

Biogen Inc (NASDAQ:BIIB, XETRA:IDP) has been upgraded to ‘Buy’ from ‘Neutral’ by UBS analysts, who also raised their price ...

Biogen (BIIB) has reached a deal worth up to $850M with TJ Bio to acquire exclusive rights in Greater China for felzartamab, an antibody therapy designed to target various immune-mediated disorders, ...

April 20 (Reuters) - Biogen said on Monday it had agreed to pay up to $850 million to acquire exclusive rights in Greater ...

Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building ...

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights ...

Biogen (BIIB) stock gains as Piper Sandler upgrades the company, citing positives in the company’s recent deal to acquire eye ...

Biogen has agreed to acquire ​Apellis ​Pharmaceuticals ​for about $5.6 billion in cash, expanding its portfolio ⁠of ‌rare-disease medicines.

When a biopharma company known for its expertise in a specific domain turns to a collaborator to expand its capabilities in that area, it serves as strong validation of the partner’s technology. | The ...

Biogen has agreed to pay up to $850 million to acquire TJ Bio's exclusive rights to felzartamab in the Greater China region, giving it worldwide rights to the investigational drug that is currently in ...

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner -- Advancing felzartamab -- a ...